Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast anatolia survey with six hemodialysis centers

Erdoğdu, Halil İbrahim; Atalay, Eray; Gürsoy, Gül; Canbakan, Başol; Aktürk, Serkan; Yazici, Canan; Yücel, Orhan Kemal; Mersin, Sinan; Ucer, Sengul; Merhametsiz, Özgür; Öner, Can; Erat, Merve

doi:10.1007/s10157-018-1676-x

Cited by 6 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A finding of interest in our study is the link between the humoral response to the Pfizer BNT162B2 Comirnaty ® vaccine, and previous response to Hepatitis B vaccination. Patients who were non-responders to HBV vaccine were those who also displayed the lowest level of anti SARS-CoV-2 antibodies, suggesting that similar mechanisms are involved in the failure to mount an immune response to these two vaccines [15][16][17] . Taken together, these findings suggest that the humoral response to the Pfizer BNT162B2 Comirnaty ® vaccine in patients undergoing hemodialysis is guided by factors related to the uremic condition, leading to delayed humoral response of lower magnitude.…”

Section: Discussionmentioning

confidence: 99%

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Danthu

Hantz

Dahlem

et al. 2021

JASN

145

149

View full text Add to dashboard Cite

Background Kidney transplant recipients and patients receiving hemodialysis are immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded from clinical trials of SARS-CoV-2 mRNA vaccines. Antibody titers and rates of seroconversion following vaccination are lower among patients with chronic kidney disease and those taking immunosuppressants compared with controls. Data are lacking regarding their humoral response to vaccination to prevent COVID-19. Methods This investigation of early serological response after COVID-19 vaccination with the Pfizer/BioNTech (BNT162b2) mRNA vaccine included 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and 7 healthy controls. We recorded data from the medical file for various clinical parameters, including response to hepatitis B vaccination, and measured antibody titers against SARS-CoV-2 at 0, 14, 28, 36 and 58 days after the first injection. Results In controls, we detected antibodies at a positive level (>13 arbitrary units per milliliter [AU/ml]) at day 14 postinjection, which increased progressively to peak at day 36 (1082 AU/ml; interquartile range [IQR], 735.0-1662.0]). Patients undergoing hemodialysis had lower titers that peaked at day 58 (276 AU/ml [IQR, 83.4-526.0]. We detected a positive antibody level in only three transplant recipients at day 36. In hemodialysis patients, those younger than 75 years had a higher antibody response versus those older than 75 years and serum albumin and Kt/V were positively correlated with serological response (P< 0.043 and P<0.019, respectively); nonresponders to HBV vaccine had the lowest anti-SARS-CoV-2 antibody titers. Conclusions Our results suggest that the postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients and is reduced by the uremic condition in patients undergoing hemodialysis.

show abstract

Section: Discussionmentioning

confidence: 99%

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Danthu

Hantz

Dahlem

et al. 2021

JASN

145

149

View full text Add to dashboard Cite

show abstract

“…Nursing staff who work most closely with the HD patients equally need to be aware of factors that adversely influence responsiveness of HD patients to hepatitis B immunization. Recent research data indicate that the dialysis staff should be alert to the presence of concomitant hepatitis C infection, hypoalbuminemia, obesity, old age, insufficient urea reduction rate and long duration of HD as risk factors for poor response to hepatitis B vaccination [16,17]. As a result, proper patient profiling assists in early identification of those who are most likely to benefit from intensive monitoring of their antibody titer, increased frequency and higher dosage of the vaccine delivery.…”

Section: Discussionmentioning

confidence: 99%

Awareness and Practice of Vaccination of Chronic Hemodialysis Patients by Specialist Nephrology Practitioners in Nigeria: A Cross-Sectional Survey

Akinbodewa¹,

Adejumo²

2019

JEGH

View full text Add to dashboard Cite

Vaccination of hemodialysis (HD) patients reduces mortality and infection transmission in dialysis units, but its practice is perceivably poor in Nigeria with no study quantifying the level of awareness and practice to date. A questionnaire-based, cross-sectional study on nephrologists was designed. Average group performance scores were calculated for each professional group. Data were analyzed using Statistical Package for the Social Sciences version 20.0 software. The mean age of a total of 142 respondents was 40.7 ± 8.4 years. The average group performance scores for consultants, senior registrars, medical officers, dialysis nurses, and general nurses were 63.4, 63.4, 50.3, 43.4, and 43.4, respectively. Six facilities (11.1%) had active vaccination protocol against hepatitis B virus infection (HBV) alone. These comprised 4/8 (50%) private facilities and 2/46 (4.3%) public hospitals. One public tertiary hospital (2.2%) had an active vaccination protocol against Streptococcus pneumoniae. Awareness and practice of vaccination of HD patients by nephrologists is low. Practice of vaccination of HD patients is better in the private sector.

show abstract

“…In literature, it is stated that besides educations on vaccines, seroconversion rates of hepatitis B are also affected by age, gender, duration of dialysis, hemofiltration, vitamin D deficiency, high-dose erythropoietin, Levamisole supplement, renal replacement therapy option, systemic diseases, serum albumin level being <3.5g/dl, obesity and stage of chronic kidney disease (2)(3)(4)(5). In literature, it is emphasized that "Hepatitis B vaccination, stringent precautions in all dialysis centres, intense health education to both patients and medical staff will be beneficial to lower the seroconversion and high financial burden on end-stage renal disease patients" (6).…”

Section: Introductionmentioning

confidence: 99%

Use of Regular Vaccination Schedule in Hemodialysis Patients and Awareness

Topbaş¹,

Turan²,

Bay³

et al. 2020

ndthdt

View full text Add to dashboard Cite

show abstract

Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast anatolia survey with six hemodialysis centers

Cited by 6 publications

References 22 publications

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Awareness and Practice of Vaccination of Chronic Hemodialysis Patients by Specialist Nephrology Practitioners in Nigeria: A Cross-Sectional Survey

Use of Regular Vaccination Schedule in Hemodialysis Patients and Awareness

Contact Info

Product

Resources

About